ArticlePloS one2025
Phenotypic identification of Metallo-ß- lactamase resistance Gram negative bacteria from a clinical specimen in Sidama, Ethiopia.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prevalence, multidrug resistance patterns, and carbapenemase-encoding genes of carbapenemase-producingSAGE open medicine · 2026Review
- Molecular detection and ultrastructure characterization of some drug-resistant Gram-negative bacteria isolated from bladder cancer patients.BMC microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetallo-beta lactamase resistance is one of the carbapenem resistances that worsen the world nowadays. A new variant of carbapenem-resistant has only limited reports from Africa including Ethiopia. This study aimed to determine Metallo -ß- lactamase resistance Gram-negative bacteria in Hawassa University Comprehensive Specialized Hospital January-June 2023.
methodA cross-sectional study was conducted in which consecutive patients infected with Gram-negative bacteria were included in the study. A structured questionnaire was used to collect the data with oriented nurses if the patients/or caregivers gave consent to participate in the study. Clinical specimens are processed based on the standard operating procedure of the Microbiology laboratory and Clinical laboratory standard institute guidelines. Culture and sensitivity testing was used to isolate the bacteria. Gram staining and biochemical tests was used to identify the bacteria to genus and species. Kirby disc diffusion technique was used to determine the susceptibility of antibiotics. Statistical Software for Social Science (SPSS) version 21 is used for data entry and analysis. Descriptive statistics and logistic regression were used to interpret the data. The odds ratio at 95% confidence interval (CI) and p-value < 0.05 were taken as a statistically significant association.
resultOur study included 153 isolates from different specimens, 83 (54.2%) were from male patients and 70 (45.8%) were from females. Klebsiella pneumonia was the predominant 43, followed by Escherichia coli 32, Acinetobacter spp 25, Pseudomonas spp 15, Enterobacter agglomerus 9, Klebsiella ozaenae 6, Enterobacter cloacae 5, Klebsiella oxytoca 4, (Klebsiella rhinoscleromatis, Proteus mirabilis and Morganella morganii) 3, Providencia stuartii 2 and (Citrobacter spp & Proteus vulgaris) 1. The rates of multi, extensive and pan-drug resistance bacteria accounted for 128/153 (83.7%), 77 /153(50.3%), and 26/153 (17.0%), respectively. Carbapenem resistance was 21 (13.7%), of this 7.2% were Enterobacteriaceae, 5.2% were Acetinobacter spp. and 1.3% Pseudomonas spp. Metallo-beta-lactamase was 17 (11.1%), of this, Enterobacteriaceae were 9(5.9%), Acetinobacter spp. 7(4.6%), and Pseudomonas spp. 1(0.7%). There were no variables statistically significantly associated with metallo-beta-lactamase-resistant.
conclusionOur study revealed that Metallo-beta-lactamase resistance was circulating in the study area. There was a high rate of carbapenem resistance, multi, extensive and pan-drug resistance. Therefore, a measure should be taken to alleviate the emerging threat that leaves the patients without the option of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.